Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14215018 | 1.00 | GSR (0.59) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL13084137 | 1.00 | GSR (0.59) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL18739868 | 0.93 | GSR (0.50) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL19881428 | 0.84 | — | — | |
| SCHEMBL5501937 | 0.79 | GSR (0.55) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL15896442 | 0.78 | DPP7 (0.48) | DPP7DPP8DPP9DPP4 | |
| SCHEMBL26606339 | 0.78 | GSR (0.53) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL17365415 | 0.78 | GSR (0.53) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL7294151 | 0.78 | GSR (0.53) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL27005 | 0.78 | GSR (0.53) | GSRGNAI3GNAO1GNAI1RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | GSR 1529/4885GNAI3 938/4885GNAO1 739/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | GSR 1217/4885GNAI3 1023/4885GNAO1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.